Detection and quantification of 56 new psychoactive substances in whole blood and urine by LC-MS/MS

Bioanalysis

Volumn 7, Issue 9, 2015, Pages 1119-1136

  Ambach, Lars ^a   Hernández Redondo, Ana ^a   König, Stefan ^a   Angerer, Verena ^b   Schürch, Stefan ^a   Weinmann, Wolfgang ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 2,5 DIMETHOXY 4 ETHYLAMPHETAMINE; 2,5 DIMETHOXY 4 METHYLAMPHETAMINE; 2,5 DIMETHOXYAMPHETAMINE; 3',4' METHYLENEDIOXYPYROVALERONE; 3',4'METHYLENEDIOXY ALPHA PYRROLIDINOPROPIOPHENONE; 3,4 DIMETHOXYAMPHETAMINE; 3,4 METHYLENEDIOXY N,N DIMETHYLAMPHETAMINE; 3,4,5 TRIMETHOXYAMPHETAMINE; 4 FLUOROBENZYLPIPERAZINE; 4 METHOXYAMPHETAMINE; 4 METHYLTHIOAMPHETAMINE; 4' METHYLMETHCATHINONE; AMPHETAMINE DERIVATIVE; BROLAMFETAMINE; BUTYLONE; CATHINONE; FLEPHEDRONE; METHYLENEDIOXYBENZYLPIPERAZINE; METHYLONE; N ETHYLAMPHETAMINE; N,N DIMETHYLTRYPTAMINE; NEW DRUG; NOREPHEDRINE; PHENCYCLIDINE; PSYCHOTROPIC AGENT; PYROVALERONE; TRYPTAMINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BLOOD ANALYSIS; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG SCREENING; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETER; MASS SPECTROMETRY; PROCESS DEVELOPMENT; QUANTITATIVE ANALYSIS; URINALYSIS; VALIDATION PROCESS; BLOOD; HUMAN; PROCEDURES; TANDEM MASS SPECTROMETRY; URINE;

BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, LIQUID; HUMANS; PSYCHOTROPIC DRUGS; TANDEM MASS SPECTROMETRY; URINALYSIS;

EID: 84930579232     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.15.48     Document Type: Article

References (84)

1. EMCDDA. European Drug Report 2014-Trends and Developments. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Luxembourg (2014). www.emcdda.europa.eu
2. UNODC. 2014 Global Synthetic Drugs Assessment. United Nations Office on Drugs and Crime (UNODC), Vienna, Austria (2014). www.unodc.org
3. National Forensic Laboratory Information System. Emerging 2C-phenethylamines, piperazines, and tryptamines in NFLIS, 2006-2011. United States Drug Enforcement Administration (DEA), Springfield, VA, USA (2012). www.deadiversion.usdoj.gov
4. Hill SL, Thomas SHL. Clinical toxicology of newer recreational drugs. Clin. Toxicol. 49(8), 705-719 (2011).
5. Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J. Med. Toxicol. 8(1), 33-42 (2012).
6. Banks ML, Worst TJ, Rusyniak DE, Sprague JE. Synthetic cathinones ("Bath salts"). J. Emerg. Med. 46(5), 632-642 (2014).
7. Mugele J, Nañagas KA, Tormoehlen LM. Serotonin syndrome associated with MDPV use: a case report. Ann. Emerg. Med. 60(1), 100-102 (2012).
8. Warrick BJ, Wilson J, Hedge M, Freeman S, Leonard K, Aaron C. Lethal serotonin syndrome after methylone and butylone ingestion. J. Med. Toxicol. 8(1), 65-68 (2012).
9. Vevelstad M, Øiestad EL, Middelkoop G et al. The PMMA epidemic in Norway: comparison of fatal and non-fatal intoxications. Forensic Sci. Int. 219(1-3), 151-157 (2012).
10. Benzie F, Hekman K, Cameron L et al. Emergency department visits after use of a drug sold as "bath salts"- Michigan, USA, November 13, 2010-March 31, 2011. MMWR Morb. Mortal. Wkly Rep. 60(19), 624-627 (2011).
11. Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3, 4- methylenedioxypyrovalerone. Ann. Emerg. Med. 60(1), 103-105 (2012).
12. James D, Adams RD, Spears R et al. Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service. Emerg. Med. J. 28(8), 686-689 (2011).
13. Elliott S, Evans J. A 3 year review of new psychoactive substances in casework. Forensic Sci. Int. 243C, 55-60 (2014).
14. Gregg RA, Rawls SM. Behavioral pharmacology of designer cathinones: a review of the preclinical literature. Life Sci. 97(1), 27-30 (2014).
15. Miotto K, Striebel J, Cho AK, Wang C. Clinical and pharmacological aspects of bath salt use: a review of the literature and case reports. Drug Alcohol Depend. 132(1-2), 1-12 (2013).
16. Ross EA, Reisfield GM, Watson MC, Chronister CW, Goldberger BA. Psychoactive "bath salts" intoxication with methylenedioxypyrovalerone. Am. J. Med. 125(9), 854-858 (2012).
17. Sivagnanam K, Chaudari D, Lopez P, Sutherland ME, Ramu VK. "Bath salts" induced severe reversible cardiomyopathy. Am. J. Case Rep. 14, 288-291 (2013).
18. Russo R, Marks N, Morris K, King H, Gelvin A, Rooney R. Life-threatening necrotizing fasciitis due to 'bath salts' injection. Orthopedics 35(1), E124-E127 (2012).
19. Carmo H, Hengstler JG, de Boer D et al. Metabolic pathways of 4-bromo-2, 5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human. Toxicology 206(1), 75-89 (2005).
20. Sacks J, Ray MJ, Williams S, Opatowsky MJ. Fatal toxic leukoencephalopathy secondary to overdose of a new psychoactive designer drug 2C-E ("Europa"). Proc. (Bayl. Univ. Med. Cent.). 25(4), 374-376 (2012).
21. Arbo MD, Bastos ML, Carmo HF. Piperazine compounds as drugs of abuse. Drug Alcohol Depend. 122(3), 174-185 (2012).
22. Alansari M, Hamilton D. Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report. N. Z. Med. J. 119(1233), U1959-U1959 (2006).
23. Wood DM, Dargan PI, Button J et al. Collapse, reported seizure-and an unexpected pill. Lancet 369(9571), 1490-1490 (2007).
24. Corkery JM, Durkin E, Elliott S, Schifano F, Ghodse AH. The recreational tryptamine 5-MeO-DALT (N, N-diallyl-5-methoxytryptamine): a brief review. Prog. Neuropsychopharmacol. Biol. Psychiatry 39(2), 259-262 (2012).
25. Morgan CJA, Curran HV. Independent scientific committee on drugs. Ketamine use: a review. Addiction 107(1), 27-38 (2012).
26. Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien (Betäubungsmittelverzeichnisverordnung, BetmVV-EDI). 812.121.11 (2011).
27. Prevenção e Proteção Contra a Publicidade e Comércio das Novas Substâncias Psicoativas. (DL N.o 54/2013) (2013).
28. Lista de Novas Substâncias Psicoativas. N.o 154/2013 (2013).
29. Misuse of Drugs Act (1971). www.legislation.gov.uk
30. Federal Analogue Act. (99-570) (1986). www.unodc.org
31. Bundesgesetz über den Schutz vor Gesundheitsgefahren im Zusammenhang mit Neuen Psychoaktiven Substanzen (Neue-Psychoaktive-Substanzen-Gesetz, NPSG) (2012).
32. Verordnung des Bundesministers für Gesundheit, mit der eine Verordnung über Neue Psychoaktive Substanzen erlassen und die Verordnung betreffend das Inverkehrbringen, den Import und das Verbringen von Räuchermischungen, die cannabinomimetisch wirksame Stoffe enthalten, aufgehoben wird. BGBl. II Nr. 468/2011 (2012).
33. Sundström M, Pelander A, Angerer V, Hutter M, Kneisel S, Ojanperä I. A high-sensitivity ultra-high performance liquid chromatography/high-resolution time-of-flight mass spectrometry (UHPLC-HR-TOFMS) method for screening synthetic cannabinoids and other drugs of abuse in urine. Anal. Bioanal. Chem. 405(26), 8463-8474 (2013).
34. Hutter M, Broecker S, Kneisel S, Auwärter V. Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in 'herbal mixtures' using LC-MS/MS techniques. J. Mass Spectrom. 47(1), 54-65 (2012).
35. Hutter M, Kneisel S, Auwärter V, Neukamm MA. Determination of 22. synthetic cannabinoids in human hair by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 903, 95-101 (2012).
36. Huppertz LM, Kneisel S, Auwärter V, Kempf J. A comprehensive library-based, automated screening procedure for 46 synthetic cannabinoids in serum employing liquid chromatography-quadrupole ion trap mass spectrometry with high-temperature electrospray ionization. J. Mass. Spectrom. 49(2), 117-127 (2014).
37. Kneisel S, Speck M, Moosmann B, Corneillie TM, Butlin NG, Auwärter V. LC/ESI-MS/MS method for quantification of 28 synthetic cannabinoids in neat oral fluid and its application to preliminary studies on their detection windows. Anal. Bioanal. Chem. 405(14), 4691-4706 (2013).
38. Al-Saffar Y, Stephanson NN, Beck O. Multicomponent LC- MS/MS screening method for detection of new psychoactive drugs, legal highs, in urine-experience from the Swedish population. J. Chromatogr. B 930, 112-120 (2013).
39. Paul M, Ippisch J, Herrmann C, Guber S, Schultis W. Analysis of new designer drugs and common drugs of abuse in urine by a combined targeted and untargeted LC- HR-QTOFMS approach. Anal. Bioanal. Chem. 406(18), 4425-4441 (2014).
40. O'Byrne PM, Kavanagh PV, McNamara SM, Stokes SM. Screening of stimulants including designer drugs in urine using a liquid chromatography tandem mass spectrometry system. J. Anal. Toxicol. 37(2), 64-73 (2013).
41. Montesano C, Sergi M, Moro M et al. Screening of methylenedioxyamphetamine- and piperazine-derived designer drugs in urine by LC-MS/MS using neutral loss and precursor ion scan. J. Mass. Spectrom. 48(1), 49-59 (2013).
42. LaPointe J, Musselman B, O'Neill T, Shepard JRE. Detection of "Bath Salt" synthetic cathinones and metabolites in urine via DART-MS and solid phase microextraction. J. Am. Soc. Mass Spectrom. 26(1), 159-165 (2014).
43. Concheiro M, Anizan S, Ellefsen K, Huestis MA. Simultaneous quantification of synthetic cathinones and metabolites in urine by liquid chromatography-high resolution mass spectrometry. Anal. Bioanal. Chem. 405(29), 9437-9448 (2013).
44. Kerrigan S, Mott A, Jatzlau B et al. Designer psychostimulants in urine by liquid chromatography-tandem mass spectrometry. J. Forensic Sci. 59(1), 175-183 (2014).
45. Anizan S, Ellefsen K, Concheiro M et al. 3, 4- Methylenedioxypyrovalerone (MDPV) and metabolites quantification in human and rat plasma by liquid chromatography-high resolution mass spectrometry. Anal. Chim. Acta 827, 54-63 (2014).
46. Antia U, Tingle MD, Russell BR. Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. J. Forensic Sci. 55(5), 1311-1318 (2010).
47. Beyer J, Peters FT, Kraemer T, Maurer HH. Detection and validated quantification of nine herbal phenalkylamines and methcathinone in human blood plasma by LC-MS/MS with electrospray ionization. J. Mass. Spectrom. 42(2), 150-160 (2007).
48. Peters FT, Schaefer S, Staack RF, Kraemer T, Maurer HH. Screening for and validated quantification of amphetamines and of amphetamine-and piperazine-derived designer drugs in human blood plasma by gas chromatography/mass spectrometry. J. Mass Spectrom. 38(6), 659-676 (2003).
49. Swortwood MJ, Boland DM, DeCaprio AP. Determination of 32 cathinone derivatives and other designer drugs in serum by comprehensive LC-QQQ-MS/MS analysis. Anal. Bioanal. Chem. 405(4), 1383-1397 (2013).
50. Wohlfarth A, Weinmann W, Dresen S. LC-MS/MS screening method for designer amphetamines, tryptamines, and piperazines in serum. Anal. Bioanal. Chem. 396(7), 2403-2414 (2010).
51. Ammann D, McLaren JM, Gerostamoulos D, Beyer J. Detection and quantification of new designer drugs in human blood: Part 2-Designer cathinones. J. Anal. Toxicol. 36(6), 381-389 (2012).
52. Castro AL, Tarelho S, Silvestre A, Teixeira HM. Simultaneous analysis of some club drugs in whole blood using solid phase extraction and gas chromatography-mass spectrometry. J. Forensic Leg. Med. 19(2), 77-82 (2012).
53. Sørensen LK. Determination of cathinones and related ephedrines in forensic whole-blood samples by liquid- chromatography-electrospray tandem mass spectrometry. J. Chromatogr. B 879(11-12), 727-736 (2011).
54. Martin M, Muller JF, Turner K, Duez M, Cirimele V. Evidence of mephedrone chronic abuse through hair analysis using GC/MS. Forensic Sci. Int. 218(1-3), 44-48 (2012).
55. Shah SAB, Deshmukh NIK, Barker J et al. Quantitative analysis of mephedrone using liquid chromatography tandem mass spectroscopy: application to human hair. J. Pharm. Biomed. Anal. 61, 64-69 (2012).
56. Rust KY, Baumgartner MR, Dally AM, Kraemer T. Prevalence of new psychoactive substances: a retrospective study in hair. Drug Test Anal. 4(6), 402-408 (2012).
57. Strano-Rossi S, Odoardi S, Fisichella M, Anzillotti L, Gottardo R, Tagliaro F. Screening for new psychoactive substances in hair by ultrahigh performance liquid chromatography-electrospray ionization tandem mass spectrometry. J. Chromatogr. A 1372C, 145-156 (2014).
58. Choi H, Baeck S, Jang M, Lee S, Choi H, Chung H. Simultaneous analysis of psychotropic phenylalkylamines in oral fluid by GC-MS with automated SPE and its application to legal cases. Forensic Sci. Int. 215(1-3), 81-87 (2012).
59. Kim JY, Cheong JC, Lee JI, Son JH, In MK. Rapid and simple GC-MS method for determination of psychotropic phenylalkylamine derivatives in nails using micro-pulverized extraction. J. Forensic Sci. 57(1), 228-233 (2012).
60. Ambach L, Hernández Redondo A, König S, Weinmann W. Rapid and simple LC-MS/MS screening of 64 novel psychoactive substances using dried blood spots. Drug Test Anal. 6(4), 367-375 (2014).
61. Peters FT, Martinez-Ramirez JA. Analytical toxicology of emerging drugs of abuse. Ther. Drug Monit. 32(5), 532-539 (2010).
62. Vorce SP, Sklerov JH. A general screening and confirmation approach to the analysis of designer tryptamines and phenethylamines in blood and urine using GC-EI-MS and HPLC-electrospray-MS. J. Anal. Toxicol. 28(6), 407-410 (2004).
63. Wohlfarth A, Weinmann W. Bioanalysis of new designer drugs. Bioanalysis 2(5), 965-979 (2010).
64. Marinetti LJ, Antonides HM. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J. Anal. Toxicol. 37(3), 135-146 (2013).
65. Meyer MR, Caspar A, Brandt SD, Maurer HH. A qualitative/quantitative approach for the detection of 37 tryptamine-derived designer drugs, 5 beta-carbolines, ibogaine, and yohimbine in human urine and plasma using standard urine screening and multi-analyte approaches. Anal. Bioanal. Chem. 406(1), 225-237 (2014).
66. Peters FT, Hartung M, Herbold M, Schmitt G, Daldrup T, Musshoff F. Anforderungen an die Validierung von Analysenmethoden. Toxichem. Krimtech. 76(3), 185-208 (2009).
67. Guidance document on analytical quality control and validation procedures for pesticide residues analysis in food and feed. European Commission (2014). http://ec.europa.eu
68. Schmitt G, Herbold M, Peters FT. VALISTAT Software, Version 2.00.1. Arvecon GmbH, Walldorf, Germany (2010).
69. Annesley TM. Ion suppression in mass spectrometry. Clin. Chem. 49(7), 1041-1044 (2003).
70. Bonfiglio R, King RC, Olah TV, Merkle K. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun. Mass Spectrom. 13(12), 1175-1185 (1999).
71. Dams R, Huestis MA, Lambert WE, Murphy CM. Matrix effect in bio-analysis of illicit drugs with LC-MS/ MS: influence of ionization type, sample preparation, and biofluid. J. Am. Soc. Mass Spectrom. 14(11), 1290-1294 (2003).
72. Müller C, Schäfer P, Störtzel M, Vogt S, Weinmann W. Ion suppression effects in liquid chromatography-electrospray- ionisation transport-region collision induced dissociation mass spectrometry with different serum extraction methods for systematic toxicological analysis with mass spectra libraries. J. Chromatogr. B. 773(1), 47-52 (2002).
73. Ambach L, Weinmann W. Legal-Highs.ch (2014). www.legal-highs.ch
74. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal. Chem. 75(13), 3019-3030 (2003).
75. Favretto D, Pascali JP, Tagliaro F. New challenges and innovation in forensic toxicology: focus on the "New Psychoactive Substances". J. Chromatogr. A 1287, 84-95 (2013).
76. Peters FT. Recent developments in urinalysis of metabolites of new psychoactive substances using LC-MS. Bioanalysis 6(15), 2083-2107 (2014).
77. World Drug Report 2013. United Nations Office on Drugs and Crime (UNODC), Vienna, Austria (2013). www.unodc.org
78. Huber L. Validation of Analytical Methods-a Primer. (2010). www.chem.agilent.com
79. Scientific Working Group for Forensic Toxicology. Standard practices for method validation in forensic toxicology. J. Anal. Toxicol. 37(7), 452-474 (2013).
80. Dresen S, Ferreirós N, Gnann H, Zimmermann R, Weinmann W. Detection and identification of 700 drugs by multi-target screening with a 3200 Q TRAP LC-MS/MS system and library searching. Anal. Bioanal. Chem. 396(7), 2425-2434 (2010).
81. Dresen S, Gergov M, Politi L, Halter C, Weinmann W. ESI-MS/MS library of 1, 253 compounds for application in forensic and clinical toxicology. Anal. Bioanal. Chem. 395(8), 2521-2526 (2009).
82. Dresen S, Kempf J, Weinmann W. Electrospray-ionization MS/MS library of drugs as database for method development and drug identification. Forensic Sci. Int. 161(2-3), 86-91 (2006).
83. Oberacher H, Weinmann W, Dresen S. Quality evaluation of tandem mass spectral libraries. Anal. Bioanal. Chem. 400(8), 2641-2648 (2011).
84. Takahashi M, Nagashima M, Suzuki J, Seto T, Yasuda I, Yoshida T. Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography-mass spectrometry. Talanta 77(4), 1245-1272 (2009).